The proposed study is a 3-site, 12-week, novel, feasibility, investigation of patients who
have co-occurring diagnoses of schizophrenia and current substance use disorder (alcohol,
cocaine, heroin, or cannabis). Eighty patients will be randomly assigned to switch to
brexpiprazole (the brexpiprazole group) or remain on the same antipsychotic treatment (the
control group). The study will be conducted at 3 sites in the US. The investigators expect to
enroll 80 subjects across 3 sites. UMass Medical School, Worcester MA is the lead site.
Sub-sites include Massachusetts General Hospital (MGH) and the University of North Carolina
at Chapel Hill (UNC).
Phase:
Phase 4
Details
Lead Sponsor:
University of Massachusetts, Worcester
Collaborators:
Massachusetts General Hospital Otsuka Pharmaceutical Co., Ltd. University of North Carolina, Chapel Hill